Shares of Horizon Pharma PLC (NASDAQ:HZNP) have been given an average rating of “Buy” by the sixteen analysts that are covering the company, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $18.67.

A number of research firms have recently weighed in on HZNP. UBS AG set a $16.00 price target on Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Wednesday, June 7th. Mizuho reaffirmed a “neutral” rating and set a $9.00 price target (down from $10.00) on shares of Horizon Pharma PLC in a research note on Wednesday, August 9th. BMO Capital Markets reaffirmed an “outperform” rating and set a $18.00 price target (up from $17.00) on shares of Horizon Pharma PLC in a research note on Thursday, August 10th. Zacks Investment Research raised Horizon Pharma PLC from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Piper Jaffray Companies set a $18.00 price target on Horizon Pharma PLC and gave the stock a “buy” rating in a research note on Sunday, September 10th.

Several hedge funds have recently modified their holdings of HZNP. BlackRock Inc. raised its stake in shares of Horizon Pharma PLC by 68,479.5% in the 1st quarter. BlackRock Inc. now owns 13,261,212 shares of the biopharmaceutical company’s stock valued at $196,001,000 after acquiring an additional 13,241,875 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Horizon Pharma PLC by 119.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 6,265,608 shares of the biopharmaceutical company’s stock valued at $74,373,000 after acquiring an additional 3,409,411 shares in the last quarter. William Blair Investment Management LLC bought a new position in shares of Horizon Pharma PLC in the 2nd quarter valued at approximately $23,557,000. Balyasny Asset Management LLC bought a new position in shares of Horizon Pharma PLC in the 2nd quarter valued at approximately $13,958,000. Finally, Highbridge Capital Management LLC raised its stake in shares of Horizon Pharma PLC by 128.2% in the 1st quarter. Highbridge Capital Management LLC now owns 1,545,169 shares of the biopharmaceutical company’s stock valued at $22,837,000 after acquiring an additional 867,927 shares in the last quarter. 82.30% of the stock is currently owned by institutional investors and hedge funds.

Shares of Horizon Pharma PLC (NASDAQ:HZNP) traded down 1.46% on Friday, reaching $12.11. 7,899,141 shares of the company traded hands. The firm has a 50-day moving average of $12.81 and a 200-day moving average of $13.04. The company’s market capitalization is $1.98 billion. Horizon Pharma PLC has a 52-week low of $9.45 and a 52-week high of $21.98.

Horizon Pharma PLC (NASDAQ:HZNP) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.29. Horizon Pharma PLC had a positive return on equity of 22.85% and a negative net margin of 42.40%. The firm had revenue of $289.51 million during the quarter, compared to analyst estimates of $237.01 million. During the same period last year, the company posted $0.56 EPS. The business’s quarterly revenue was up 12.5% compared to the same quarter last year. On average, equities research analysts forecast that Horizon Pharma PLC will post $1.08 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Horizon Pharma PLC (HZNP) Receives Consensus Recommendation of “Buy” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/16/horizon-pharma-plc-hznp-receives-consensus-recommendation-of-buy-from-analysts-2.html.

Horizon Pharma PLC Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Analyst Recommendations for Horizon Pharma PLC (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.